MPEG1, macrophage expressed 1, 219972

N. diseases: 98; N. variants: 0
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0019207
Disease: Hepatoma, Morris
Hepatoma, Morris
0.300 Biomarker disease CTD_human Expression profiling and identification of novel genes in hepatocellular carcinomas. 11420682 2001
CUI: C0019208
Disease: Hepatoma, Novikoff
Hepatoma, Novikoff
0.300 Biomarker disease CTD_human Expression profiling and identification of novel genes in hepatocellular carcinomas. 11420682 2001
CUI: C0023904
Disease: Liver Neoplasms, Experimental
Liver Neoplasms, Experimental
0.300 Biomarker phenotype CTD_human Expression profiling and identification of novel genes in hepatocellular carcinomas. 11420682 2001
CUI: C0086404
Disease: Experimental Hepatoma
Experimental Hepatoma
0.300 Biomarker disease CTD_human Expression profiling and identification of novel genes in hepatocellular carcinomas. 11420682 2001
CUI: C0026703
Disease: Mucopolysaccharidoses
Mucopolysaccharidoses
0.100 Biomarker disease BEFREE Background Mucopolysaccharidosis type 1 (MPS1) is a rare debilitating multisystem lysosomal disorder resulting due to the deficiency of α-L-iduronidase enzyme (IDUA), caused by recessive mutations in the IDUA gene. 31473686 2019
CUI: C0026703
Disease: Mucopolysaccharidoses
Mucopolysaccharidoses
0.100 Biomarker disease BEFREE Mucopolysaccharidosis type 1 (MPS-1), also known as Hurler's disease, is a congenital metabolic disorder caused by a mutation in the alpha-L-iduronidase (IDUA) gene, which results in the loss of lysosomal enzyme function for the degradation of glycosaminoglycans. 31065277 2019
CUI: C0026703
Disease: Mucopolysaccharidoses
Mucopolysaccharidoses
0.100 GeneticVariation disease BEFREE We retrospectively reviewed the clinical ophthalmologic features and electrodiagnostic results of 50 Taiwanese patients with a diagnosis of MPS (34 males and 16 females; age range, 1.1-34.9 years; nine with MPS I, 17 with MPS II, 17 with MPS IV, and seven with MPS VI). 30848093 2019
CUI: C0026703
Disease: Mucopolysaccharidoses
Mucopolysaccharidoses
0.100 GeneticVariation disease BEFREE Among 153 subjects enrolled in this study, 13 had a confirmative diagnosis of MPS (age range, 0.6 to 10.9 years-three with MPS I, four with MPS II, five with MPS IIIB, and one with MPS IVA). 31590383 2019
CUI: C0026703
Disease: Mucopolysaccharidoses
Mucopolysaccharidoses
0.100 Biomarker disease BEFREE Corneal clouding, causing visual impairment, is seen in nearly all patients with Mucopolysaccharidosis type 1 (MPS-1). 31786241 2019
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.100 Biomarker group BEFREE MPS-1 was correlated with advanced tumor stage, suggesting its association with CRC progression. 31506433 2019
CUI: C0086795
Disease: Pfaundler-Hurler Syndrome
Pfaundler-Hurler Syndrome
0.100 Biomarker disease BEFREE Mucopolysaccharidosis type 1 (MPS-1), also known as Hurler's disease, is a congenital metabolic disorder caused by a mutation in the alpha-L-iduronidase (IDUA) gene, which results in the loss of lysosomal enzyme function for the degradation of glycosaminoglycans. 31065277 2019
CUI: C0086795
Disease: Pfaundler-Hurler Syndrome
Pfaundler-Hurler Syndrome
0.100 Biomarker disease BEFREE The estimated global incidence of MPS1 is 1:100,000 live births for the Hurler and 1:800,000 for the Scheie phenotypes. 31473686 2019
CUI: C0026703
Disease: Mucopolysaccharidoses
Mucopolysaccharidoses
0.100 GeneticVariation disease BEFREE The aims of this study were to analyze the maxillomandibular morphology of patients with mucopolysaccharidosis (MPS) type I, II, III, IVa and VI and to evaluate the craniofacial effect of hematopoietic stem cell transplantation (HCST) in MPS I. 29046964 2018
CUI: C0026703
Disease: Mucopolysaccharidoses
Mucopolysaccharidoses
0.100 Biomarker disease BEFREE In severe MPS I (MPS IH, or Hurler syndrome) initial developmental trajectory is usually unremarkable but cognitive development shows a plateau by 2 to 4 years of age and then progressively regresses with aging. 30442188 2018
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.100 Biomarker group BEFREE To investigate how the combination of docetaxel and a Mps1 inhibitor (Cpd-5) promote tumour cell death, we treated mice transplanted with BRCA1<sup>-/-</sup>;TP53<sup>-/-</sup> mammary tumours with docetaxel and/or Cpd-5. 29736010 2018
CUI: C0086795
Disease: Pfaundler-Hurler Syndrome
Pfaundler-Hurler Syndrome
0.100 Biomarker disease BEFREE The purpose of this study was to assess the extent of the diagnostic delay in the two ultra-rare diseases, i.e., mucopolysaccharidosis I (MPS I) and III (MPS III), both of which are lysosomal storage disorders with different phenotypic severities (MPS 1 is characterized by the severe Hurler and the more attenuated non-Hurler phenotypes, MPS III is characterized by the severe rapidly progressing (RP) phenotype and more attenuated slowly progressing (SP) phenotype). 29310675 2018
CUI: C0026703
Disease: Mucopolysaccharidoses
Mucopolysaccharidoses
0.100 GeneticVariation disease BEFREE This pilot study analyzed 2862 dried blood spots (DBS) from newborns and 14 DBS from newborn patients with MPS (MPS I, n = 7; MPS II, n = 2; MPS III, n = 5). 27718145 2017
CUI: C0026703
Disease: Mucopolysaccharidoses
Mucopolysaccharidoses
0.100 Biomarker disease BEFREE Additional studies in cultured neurons from MPS I mice showed that elevated spermine was essential for the abnormal neurite overgrowth exhibited by MPS neurons. 28934395 2017
CUI: C0026703
Disease: Mucopolysaccharidoses
Mucopolysaccharidoses
0.100 Biomarker disease BEFREE This review describes the appearance and progression of neurological signs and symptoms in patients with MPS I, II, and III, based on presentations and discussions among an international group of experts during a meeting on the brain in MPS on April 28-30, 2016, and additional literature searches on this subject. 29074036 2017
CUI: C0026703
Disease: Mucopolysaccharidoses
Mucopolysaccharidoses
0.100 Biomarker disease BEFREE Mucopolysaccharidosis type 1 (MPS1) is an inherited lysosomal storage disorder caused by a deficiency in the glycosaminoglycan (GAG)-degrading enzyme α-l-iduronidase (IDUA). 28585336 2017
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.100 AlteredExpression group BEFREE On the basis of in vivo pharmacodynamic vs efficacy relationships, we predict that more than 80% inhibition of MPS1 activity for at least 24 h is required to achieve tumour stasis or regression by CCT271850. 28334731 2017
CUI: C0086795
Disease: Pfaundler-Hurler Syndrome
Pfaundler-Hurler Syndrome
0.100 Biomarker disease BEFREE A prospective cohort study was done of 9 patients with MPS I (Hurler) or VI (Maroteaux-Lamy). 28170539 2017
CUI: C0086795
Disease: Pfaundler-Hurler Syndrome
Pfaundler-Hurler Syndrome
0.100 Biomarker disease BEFREE In addition to a variety of somatic signs and symptoms, patients with rapidly progressing MPS I (Hurler), II, III, and VII can present with significant neurological manifestations, including impaired cognitive abilities, difficulties in language and speech, behavioral abnormalities, sleep problems, and/or seizures. 29128371 2017
CUI: C0026703
Disease: Mucopolysaccharidoses
Mucopolysaccharidoses
0.100 Biomarker disease BEFREE We conducted molecular analysis for 60 MPS-affected patients [MPS I (n = 30) (Hurler syndrome = 17, Hurler-Scheie syndrome = 13), and MPS II (n = 30) (severe = 18, attenuated = 12)] and identified a total of 44 [MPS I (n = 22) and MPS II (n = 22)] different pathogenic variants comprising missense, nonsense, frameshift, gross deletions and splice site variants. 27146977 2016
CUI: C0026703
Disease: Mucopolysaccharidoses
Mucopolysaccharidoses
0.100 GeneticVariation disease BEFREE MPS II was the most common form of MPS, comprising 47.4% of all MPS cases diagnosed, followed by MPS IVA (26.8%) and MPS I (16.3%). 26740238 2016